June 1st Week, 2025 Regulatory Events 🎯 Takeda and Pfizer’s brentuximab vedotin (Adcetris; CD30 ADC) + ECADD chemo regimen has been approved by the European commission for the Tx of adult patients with newly diagnosed stage IIb with risk factors/III/IV Hodgkin lymphoma. (Ref 1) ❓ Can brentuximab-based regimen be the standard of care? What are its strengths and limitations? 🎯 Tempest Therapeutics’ amezalpat (selective PPAR⍺ antagonist) has been granted an Orphan Drug Desi

Highlights from the CHMP Apr 2025 Meeting are out! ⭐ New Medicines 💊 Jazz Pharmaceuticals and BeiGene's zanidatamab (Ziihera; dual HER2-targeted BsAb) monotherapy is indicated for the treatment of adults with unresectable locally advanced or metastatic HER2+ve biliary tract cancer previously treated with at least one prior line of systemic therapy ⭐ New Biosimilars 💊 CuraTeQ Biologics' trastuzumab (Dazublys; HER2 inhibitor) is indicated for the treatment of HER2+ve metastat